Simvastatin does not improve outcomes in patients critically ill with COVID-19

1. In this randomized controlled trial, high-dose simvastatin did not reduce the need for organ support among critically ill patients with coronavirus disease 2019 (COVID-19). 2. High-dose simvastatin was associated with increased rates of serious adverse events amongst critically ill patients with COVID-19. Evidence Rating Level: 1 (Excellent) Study Rundown: Among critically ill patients who

Related Keywords

,Multifactorial Adaptive Platform Trial For Community ,Minute Medicine Inc ,Rating Level ,Multifactorial Adaptive Platform Trial ,Community Acquired Pneumonia ,Credible Interval ,Acute Respiratory Distress Syndrome ,Covid 19 ,Critical Care ,Emergency ,Icu ,Infectious Disease ,Simvastatin ,